Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 17/20 | 0.61 |
| ▸ | AGTR2 | P50052 | 17/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8081242 | 0.96 | AGTR1 (0.66) | AGTR1AGTR2PPARG | |
| SCHEMBL9133442 | 0.94 | AGTR1 (0.69) | AGTR1AGTR2PPARG | |
| SCHEMBL8089393 | 0.93 | AGTR1 (0.60) | AGTR1AGTR2PPARG | |
| SCHEMBL8089262 | 0.92 | AGTR1 (0.71) | AGTR1AGTR2PPARG | |
| SCHEMBL8088469 | 0.90 | AGTR1 (0.59) | AGTR1AGTR2PPARG | |
| SCHEMBL8091186 | 0.87 | AGTR1 (0.70) | AGTR1AGTR2 | |
| SCHEMBL8092909 | 0.86 | AGTR1 (0.59) | AGTR1AGTR2 | |
| SCHEMBL8089291 | 0.83 | AGTR1 (0.73) | AGTR1AGTR2 | |
| SCHEMBL8095012 | 0.82 | AGTR1 (0.67) | AGTR1AGTR2 | |
| SCHEMBL8700621 | 0.82 | PPARG (0.59) | AGTR1AGTR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6037349-A | HAVING ANTAGONISTIC PROPERTIES TOWARDS ANGIOTENSIN II CAN BE USED FOR THE TREATMENT OF HYPERTENSION, ALDOSTERONISM AND CARDIAC INSUFFICIENCY | MERCK PATENT GMBH (DE) | 2000-03-14 | — | — | US | disclosed |
| US-5798364-A | ANGIOTENSIN II ANTAGONIST, USEFUL FOR TREATMENT OF HYPERTENSION, ALDOSTERONISM AND CARDIAC INSUFFICIENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-08-25 | — | — | US | disclosed |